Abstract 12754: Head-to-Head Comparison of Everolimus- versus Zotarolimus-eluting Stents in Patients with de novo Coronary Artery Disease
Background: There is currently very limited data regarding head-to-head comparison of the everolimus-eluting stent (EES) (Abbot Laboratories, USA) and the zotarolimus-eluting stent (ZES) (Medtronic, USA) in the treatment of patients with coronary artery disease. We therefore set out to compare the safety and efficacy of these stents in our registry.
Methods: The study comprised 665 consecutive patients who underwent coronary artery stent implantation with ZES (n=201) or EES (n=464) at Washington Hospital Center for either stable coronary artery disease or the full spectrum of acute coronary syndromes. Patients who received a bare metal stent, paclitaxel-eluting stent, sirolimus-eluting stent, or two different drug-eluting stents were excluded. The primary endpoint was major adverse clinical events (MACE) defined as all cause mortality, Q-wave myocardial infarction (MI) or target lesion revascularization (TLR) at 6 months. The secondary endpoints were all cause mortality, TLR, target vessel revascularization (TVR), definite stent thrombosis, and the composite of all-cause mortality or Q-wave MI.
Results: The cohorts were well matched for their risk factor profiles as well as their lesion and procedure characteristics. The primary endpoint occurred in 4.1% of the EES group and 5.0 % of the ZES group (p=0.61). There were no differences in any of the components of the secondary endpoint: all-cause mortality (3.2% vs. 2.5% p=0.60), TLR (0.9% vs. 2.5% p=0.14), TVR (2.0% vs. 4.1% p=0.12), definite stent thrombosis (0.0% vs. 0.5% p=0.30) and death or Q-wave MI (3.2% vs. 2.5% p=0.60).
Conclusions: Both EES and ZES exhibit similar safety and efficacy at 6 months' follow-up in the treatment of patients with coronary artery disease.
- © 2010 by American Heart Association, Inc.